Mobile

Neoadjuvant therapy for postmenopausal women with ER and/or PgR positive breast cancer. A randomized open phase II trial evaluating the efficacy of a 6 months preoperative treatment with Letrozole ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-004007-37

Neoadjuvant therapy for postmenopausal women with ER and/or PgR positive breast cancer. A randomized open phase II trial evaluating the efficacy of a 6 months preoperative treatment with Letrozole (2.5 mg/day) with or without Zoledronic acid (4 mg every 4 weeks)

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Primary objective of the study is to demonstrate superiority of letrozole and zoledronic acid over letrozole monotherapy given as 6 months preoperative treatment with respect to tumor response. Response is defined as complete response (CR) or partial response (PR) based on mammography and/or sonography according to modified RECIST criteria at month 6.

Critère d'inclusion

  • Breast cancer by postmenopausal women

Liens